Viewing Study NCT04240002

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:45 AM
Ignite Modification Date: 2026-01-13 @ 5:22 PM
Study NCT ID: NCT04240002
Status: TERMINATED
Last Update Posted: 2025-05-28
First Post: 2020-01-21
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sponsor: Astellas Pharma Global Development, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia (AML) View
None Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation … View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ASP2215 View
None Acute Myeloid Leukemia View
None FLT3 View
None AML View
None gilteritinib View